Accord Biomaterials, Inc., based in Ann Arbor, MI, focuses upon the development of NogenTM nitric oxide materials for use in biomarker assays, diagnostic tools and blood-contacting medical devices. Nogen materials liberate nitric oxide from carrier molecules within blood known as nitrosothiols ('RSNOs'), enabling the development of tools that precisely quantitative RSNO levels in blood and vascular device coatings that resist clotting and infection due to nitric oxide’s inherent antiplatelet and antimicrobial effects. Accord collaborates with incubator MC3 Corporation, the Cleveland Clinic and best-in-class development partners and holds an exclusive license to Nogen technology from the University of Michigan. Privately-held and venture-backed, Accord is committed to accelerating clinical validation and utility of this technology. The company anticipates clinical trial initiation in Q3 2010 for its lead program. For more information, contact Kris Aalto via kaalto@accordbiomaterials.com or 734-995-9089.
